Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for dilated cardiomyopathy due to Troponin T K210 deletion
2023-509431-29-00Phase 2Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of risedronate in dilated cardiomyopathy (DCM), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Change in left ventricular ejection fraction (LVEF) at 6 months. Planned start Aug 2024; status: authorised.
02
Drugs
risedronate
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2023-509431-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509431-29-00.